禽腺病毒(FAdV)最早在安加拉哥特被报道,巴基斯坦,1987年。出于这个原因,它也被称为“安加拉病”。\"后来在中国有报道,Japan,韩国,印度,美国,加拿大,以及其他国家和地区,在全世界的家禽业造成巨大的经济损失。值得注意的是,自2015年6月以来,严重心包积水性肝炎综合征(HHS)自然爆发,与高毒力新型基因型FAdV-4感染相关,已经出现在中国大多数省份。新型病毒FAdV-4传播迅速,死亡率达30-100%,造成巨大的经济损失,威胁着绿色健康的家禽养殖业。针对FAdV-4的疫苗,特别是新兴的新型基因型,发挥关键作用,并将成为预防和控制HHS的最有效工具。已经开发和评估了各种类型的FAdV-4疫苗,如失活,活减毒,亚基,联合疫苗。他们为控制HHS做出了巨大贡献,但FAdV内交叉保护的细节和不同疫苗的免疫原性需要进一步研究.这篇综述重点介绍了FAdV-4疫苗的最新进展和有希望的未来研究新疫苗。
Fowl adenovirus (FAdV) was first reported in Angara Goth, Pakistan, in 1987. For this reason, it is also known as \"Angara disease.\" It was later reported in
China, Japan, South Korea, India, the United States, Canada, and other countries and regions, causing huge economic losses in the poultry industry worldwide. Notably, since June 2015, a natural outbreak of severe hydropericardium hepatitis syndrome (
HHS), associated with a hypervirulent novel genotype FAdV-4 infection, has emerged in most provinces of
China. The novel virus FAdV-4 spread rapidly and induced a 30-100% mortality rate, causing huge economic losses and threatening the green and healthy poultry breeding industry. Vaccines against FAdV-4, especially the emerging novel genotype, play a critical role and will be the most efficient tool for preventing and controlling
HHS. Various types of FAdV-4 vaccines have been developed and evaluated, such as inactivated, live-attenuated, subunit, and combined vaccines. They have made great contributions to the control of
HHS, but the details of cross-protection within FAdVs and the immunogenicity of different vaccines require further investigation. This review highlights the recent advances in developing the FAdV-4 vaccine and promising new vaccines for future research.